- Home
- RSLS vs IDAI Comparison
RSLS vs IDAI Comparison
Compare RSLS & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- IDAI
- Stock Information
- Founded
- RSLS 2002
- IDAI 2016
- Country
- RSLS United States
- IDAI United States
- Employees
- RSLS N/A
- IDAI N/A
- Industry
- RSLS Medical/Dental Instruments
- IDAI Computer Software: Prepackaged Software
- Sector
- RSLS Health Care
- IDAI Technology
- Exchange
- RSLS Nasdaq
- IDAI Nasdaq
- Market Cap
- RSLS 5.7M
- IDAI 4.9M
- IPO Year
- RSLS 2007
- IDAI N/A
- Fundamental
- Price
- RSLS $2.58
- IDAI $3.04
- Analyst Decision
- RSLS
- IDAI
- Analyst Count
- RSLS 0
- IDAI 0
- Target Price
- RSLS N/A
- IDAI N/A
- AVG Volume (30 Days)
- RSLS 458.6K
- IDAI 40.7K
- Earning Date
- RSLS 08-18-2025
- IDAI 08-12-2025
- Dividend Yield
- RSLS N/A
- IDAI N/A
- EPS Growth
- RSLS N/A
- IDAI N/A
- EPS
- RSLS N/A
- IDAI N/A
- Revenue
- RSLS $7,175,000.00
- IDAI $3,054,143.00
- Revenue This Year
- RSLS $52.80
- IDAI $65.46
- Revenue Next Year
- RSLS N/A
- IDAI $12.00
- P/E Ratio
- RSLS N/A
- IDAI N/A
- Revenue Growth
- RSLS N/A
- IDAI N/A
- 52 Week Low
- RSLS $2.23
- IDAI $1.43
- 52 Week High
- RSLS $303.25
- IDAI $18.75
- Technical
- Relative Strength Index (RSI)
- RSLS 45.22
- IDAI 56.45
- Support Level
- RSLS $2.35
- IDAI $2.60
- Resistance Level
- RSLS $2.56
- IDAI $2.94
- Average True Range (ATR)
- RSLS 0.25
- IDAI 0.20
- MACD
- RSLS 0.05
- IDAI -0.02
- Stochastic Oscillator
- RSLS 21.77
- IDAI 59.58
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.